Soligenix Announces $1.5 Million NCI SBIR Grant Award Supporting the Pivotal Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous TCell Lymphoma

PRINCETON N.J. Sept. 18 2017 PRNewswire Soligenix Inc. Nasdaq SNGX Soligenix or the Company a latestage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need announced toda...